GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+3.04%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$423M
AUM Growth
+$423M
(-5.4%)
Cap. Flow
-$17.9M
Cap. Flow
% of AUM
-4.24%
Top 10 Holdings %
Top 10 Hldgs %
53.11%
Holding
44
New
13
Increased
9
Reduced
9
Closed
6
Top Buys
| 1 |
BioAtla
BCAB
|
$24.8M |
| 2 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$16.1M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$15.4M |
| 4 |
Cytokinetics
CYTK
|
$14M |
| 5 |
UroGen Pharma
URGN
|
$12.6M |
Top Sells
| 1 |
Insulet
PODD
|
$28.7M |
| 2 |
United Therapeutics
UTHR
|
$16.6M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$16.2M |
| 4 |
Collegium Pharmaceutical
COLL
|
$14.6M |
| 5 |
Ocular Therapeutix
OCUL
|
$13M |
Sector Composition
| 1 | Healthcare | 94.11% |
| 2 | Real Estate | 2.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Exelixis
EXEL
$10.1B
| $32.2M | 7.51% | 1,525,000 +130,893 | +9% | +$2.77M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $31.6M | 7.36% | 530,670 +25,000 | +5% | +$1.49M |
|
|
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
| $29.4M | 6.84% | 3,375,000 -1,455,000 | -30% | -$12.7M |
|
|
4
BioAtla
BCAB
$26.7M
| $24.8M | 5.79% | +844,002 | New | +$24.8M |
|
5
Rocket Pharmaceuticals
RCKT
$354M
| $22.9M | 5.32% | 765,000 -52,040 | -6% | -$1.56M |
|
6
MacroGenics
MGNX
$112M
| $20.9M | 4.88% | 1,000,000 -378,495 | -27% | -$7.93M |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $16.1M | 3.76% | +799,999 | New | +$16.1M |
|
|
8
United Therapeutics
UTHR
$13.8B
| $16M | 3.72% | 86,667 -89,739 | -51% | -$16.6M |
|
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $15.4M | 3.59% | +85,000 | New | +$15.4M |
|
10
Travere Therapeutics
TVTX
$1.56B
| $15.2M | 3.53% | 625,000 -459,300 | -42% | -$11.1M |
|
11
AnaptysBio
ANAB
$569M
| $14.9M | 3.47% | 549,545 +149,494 | +37% | +$4.05M |
|
|
12
Cytokinetics
CYTK
$4.23B
| $14M | 3.26% | +391,429 | New | +$14M |
|
13
Biogen
BIIB
$19.4B
| $13.4M | 3.13% | 47,500 +15,000 | +46% | +$4.24M |
|
|
14
UroGen Pharma
URGN
$900M
| $12.6M | 2.94% | +750,000 | New | +$12.6M |
|
15
Dyne Therapeutics
DYN
$1.92B
| $12.1M | 2.82% | 745,000 +72,441 | +11% | +$1.18M |
|
|
SAGE
16
DELISTED
Sage Therapeutics
SAGE
| $11.9M | 2.78% | 269,010 +19,010 | +8% | +$842K |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $10.7M | 2.49% | +700,000 | New | +$10.7M |
|
|
TCDA
18
DELISTED
Tricida, Inc. Common Stock
TCDA
| $9.16M | 2.13% | 1,974,000 | – | – |
|
19
Puma Biotechnology
PBYI
$254M
| $9.11M | 2.12% | 1,300,000 | – | – |
|
20
Olema Pharmaceuticals
OLMA
$375M
| $9.07M | 2.11% | 329,086 | – | – |
|
21
Nektar Therapeutics
NKTR
$568M
| $9.06M | 2.11% | +504,691 | New | +$9.06M |
|
22
Aclaris Therapeutics
ACRS
$209M
| $9M | 2.1% | +500,000 | New | +$9M |
|
23
Rafael Holdings
RFL
$51.6M
| $8.78M | 2.04% | +285,714 | New | +$8.78M |
|
24
Dianthus Therapeutics
DNTH
$759M
| $8.52M | 1.98% | 1,170,000 +58,889 | +5% | +$429K |
|
25
CytomX Therapeutics
CTMX
$336M
| $7.64M | 1.78% | 1,500,000 +500,000 | +50% | +$2.55M |
|